Trelegy Ellipta generic
Trelegy Ellipta is an inhalable drug owned by Glaxosmithkline. This drug contains the active ingredients Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate. It was first authorized for market use on 18 September, 2017, and it is available in the form of an inhalation powder.
When will Trelegy Ellipta generic be available?
The generic version of Trelegy Ellipta is possible to come into the market after the last patent expires on 29 November, 2030. This means that the Trelegy Ellipta generic could potentially be available to the public at a lower cost by the end of 2030.
Trelegy Ellipta uses
Trelegy Ellipta is used in the long-term, once-daily, maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, and asthma in patients aged 18 years and older. Thanks to its active ingredient, umeclidinium, it inhibits the binding of acetylcholine to an acetylcholine receptor in the respiratory tract of a human when used via inhalation or topical application.
Trelegy Ellipta patent expiration
Trelegy Ellipta holds a total of 15 drug patents. Two of these patents have already expired, and the remaining patents will expire between 2022 and 2030. It's interesting to note that the expiration of the last patent of Trelegy Ellipta generic will happen on 29 November, 2030. For more detailed information, see below patent details: